Does the media refer more to ELTX or RNAC?

In the previous week, Elicio Therapeutics and Elicio Therapeutics both had 2 articles in the media. Elicio Therapeutics' average media sentiment score of 0.00 equaled Cartesian Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elicio Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cartesian Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor FATE or ELTX?

In the previous week, Fate Therapeutics had 2 more articles in the media than Elicio Therapeutics. MarketBeat recorded 4 mentions for Fate Therapeutics and 2 mentions for Elicio Therapeutics. Fate Therapeutics' average media sentiment score of 1.04 beat Elicio Therapeutics' score of 0.00 indicating that Fate Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fate Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elicio Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate ELTX or YDES?

Elicio Therapeutics currently has a consensus price target of $19.75, suggesting a potential upside of 690.00%. Given Elicio Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Elicio Therapeutics is more favorable than YD Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Elicio Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 YD Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, ELTX or YDES?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Elicio Therapeutics N/A N/A -$39.57M -$2.17 N/A YD Bio N/A N/A N/A N/A N/A

Is ELTX or YDES more profitable?

YD Bio's return on equity of 0.00% beat Elicio Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Elicio Therapeutics N/A -1,266.43% -139.94% YD Bio N/A N/A N/A

Does the media refer more to ELTX or YDES?

In the previous week, YD Bio had 4 more articles in the media than Elicio Therapeutics. MarketBeat recorded 6 mentions for YD Bio and 2 mentions for Elicio Therapeutics. YD Bio's average media sentiment score of 0.32 beat Elicio Therapeutics' score of 0.00 indicating that YD Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elicio Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral YD Bio 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ELTX or EBS?

In the previous week, Emergent Biosolutions had 12 more articles in the media than Elicio Therapeutics. MarketBeat recorded 14 mentions for Emergent Biosolutions and 2 mentions for Elicio Therapeutics. Emergent Biosolutions' average media sentiment score of 0.89 beat Elicio Therapeutics' score of 0.00 indicating that Emergent Biosolutions is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elicio Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Emergent Biosolutions 7 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BCYC or ELTX?

In the previous week, Bicycle Therapeutics and Bicycle Therapeutics both had 2 articles in the media. Bicycle Therapeutics' average media sentiment score of 0.25 beat Elicio Therapeutics' score of 0.00 indicating that Bicycle Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicycle Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Elicio Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Elicio Therapeutics (ELTX) Competitors

$2.50 -0.05 (-1.96%)

As of 09/3/2026 04:00 PM Eastern

Compare

ELTX vs. RNAC, FATE, YDES, EBS, and BCYC

Should you buy Elicio Therapeutics stock or one of its competitors? Elicio Therapeutics's main competitors and comparable companies include Cartesian Therapeutics (RNAC), Fate Therapeutics (FATE), YD Bio (YDES), Emergent Biosolutions (EBS), and Bicycle Therapeutics (BCYC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Elicio Therapeutics compare to Cartesian Therapeutics?

Elicio Therapeutics (NASDAQ:ELTX) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, risk and analyst recommendations.

Elicio Therapeutics presently has a consensus target price of $19.75, indicating a potential upside of 690.00%. Cartesian Therapeutics has a consensus target price of $32.60, indicating a potential upside of 257.46%. Given Elicio Therapeutics' higher possible upside, equities analysts plainly believe Elicio Therapeutics is more favorable than Cartesian Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elicio Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cartesian Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

35.0% of Elicio Therapeutics shares are owned by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are owned by institutional investors. 50.9% of Elicio Therapeutics shares are owned by company insiders. Comparatively, 37.2% of Cartesian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Elicio Therapeutics has a beta of 1.29, suggesting that its stock price is 29% more volatile than the broader market. Comparatively, Cartesian Therapeutics has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market.

Elicio Therapeutics has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elicio Therapeutics	N/A	-1,266.43%	-139.94%
Cartesian Therapeutics	-8,550.65%	N/A	-29.84%

In the previous week, Elicio Therapeutics and Elicio Therapeutics both had 2 articles in the media. Elicio Therapeutics' average media sentiment score of 0.00 equaled Cartesian Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elicio Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cartesian Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Elicio Therapeutics has higher earnings, but lower revenue than Cartesian Therapeutics. Cartesian Therapeutics is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.17	N/A
Cartesian Therapeutics	$2.80M	98.53	-$130.30M	-$5.94	N/A

Summary

Elicio Therapeutics beats Cartesian Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Elicio Therapeutics compare to Fate Therapeutics?

Fate Therapeutics (NASDAQ:FATE) and Elicio Therapeutics (NASDAQ:ELTX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability.

97.5% of Fate Therapeutics shares are held by institutional investors. Comparatively, 35.0% of Elicio Therapeutics shares are held by institutional investors. 4.7% of Fate Therapeutics shares are held by company insiders. Comparatively, 50.9% of Elicio Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Fate Therapeutics has a beta of 2.54, meaning that its stock price is 154% more volatile than the broader market. Comparatively, Elicio Therapeutics has a beta of 1.29, meaning that its stock price is 29% more volatile than the broader market.

In the previous week, Fate Therapeutics had 2 more articles in the media than Elicio Therapeutics. MarketBeat recorded 4 mentions for Fate Therapeutics and 2 mentions for Elicio Therapeutics. Fate Therapeutics' average media sentiment score of 1.04 beat Elicio Therapeutics' score of 0.00 indicating that Fate Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fate Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elicio Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Elicio Therapeutics has a net margin of 0.00% compared to Fate Therapeutics' net margin of -1,941.09%. Fate Therapeutics' return on equity of -65.08% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fate Therapeutics	-1,941.09%	-65.08%	-41.73%
Elicio Therapeutics	N/A	-1,266.43%	-139.94%

Elicio Therapeutics has lower revenue, but higher earnings than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fate Therapeutics	$6.65M	43.60	-$136.32M	-$1.05	N/A
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.17	N/A

Fate Therapeutics presently has a consensus target price of $5.90, suggesting a potential upside of 143.80%. Elicio Therapeutics has a consensus target price of $19.75, suggesting a potential upside of 690.00%. Given Elicio Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Elicio Therapeutics is more favorable than Fate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
Elicio Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Fate Therapeutics beats Elicio Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Elicio Therapeutics compare to YD Bio?

Elicio Therapeutics (NASDAQ:ELTX) and YD Bio (NASDAQ:YDES) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

Elicio Therapeutics currently has a consensus price target of $19.75, suggesting a potential upside of 690.00%. Given Elicio Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Elicio Therapeutics is more favorable than YD Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elicio Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
YD Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, YD Bio had 4 more articles in the media than Elicio Therapeutics. MarketBeat recorded 6 mentions for YD Bio and 2 mentions for Elicio Therapeutics. YD Bio's average media sentiment score of 0.32 beat Elicio Therapeutics' score of 0.00 indicating that YD Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elicio Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
YD Bio	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

YD Bio's return on equity of 0.00% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elicio Therapeutics	N/A	-1,266.43%	-139.94%
YD Bio	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.17	N/A
YD Bio	N/A	N/A	N/A	N/A	N/A

35.0% of Elicio Therapeutics shares are held by institutional investors. 50.9% of Elicio Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Elicio Therapeutics beats YD Bio on 5 of the 9 factors compared between the two stocks.

How does Elicio Therapeutics compare to Emergent Biosolutions?

Elicio Therapeutics (NASDAQ:ELTX) and Emergent Biosolutions (NYSE:EBS) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, media sentiment, institutional ownership and valuation.

Emergent Biosolutions has higher revenue and earnings than Elicio Therapeutics. Emergent Biosolutions is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.17	N/A
Emergent Biosolutions	$742.90M	0.43	$52.60M	-$3.55	N/A

Elicio Therapeutics has a beta of 1.29, indicating that its share price is 29% more volatile than the broader market. Comparatively, Emergent Biosolutions has a beta of 2.34, indicating that its share price is 134% more volatile than the broader market.

Elicio Therapeutics currently has a consensus price target of $19.75, indicating a potential upside of 690.00%. Emergent Biosolutions has a consensus price target of $10.00, indicating a potential upside of 60.51%. Given Elicio Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Elicio Therapeutics is more favorable than Emergent Biosolutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elicio Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Emergent Biosolutions	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.17

35.0% of Elicio Therapeutics shares are owned by institutional investors. Comparatively, 78.4% of Emergent Biosolutions shares are owned by institutional investors. 50.9% of Elicio Therapeutics shares are owned by company insiders. Comparatively, 6.0% of Emergent Biosolutions shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Emergent Biosolutions had 12 more articles in the media than Elicio Therapeutics. MarketBeat recorded 14 mentions for Emergent Biosolutions and 2 mentions for Elicio Therapeutics. Emergent Biosolutions' average media sentiment score of 0.89 beat Elicio Therapeutics' score of 0.00 indicating that Emergent Biosolutions is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elicio Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Emergent Biosolutions	7 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Elicio Therapeutics has a net margin of 0.00% compared to Emergent Biosolutions' net margin of -22.95%. Emergent Biosolutions' return on equity of 16.35% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elicio Therapeutics	N/A	-1,266.43%	-139.94%
Emergent Biosolutions	-22.95%	16.35%	6.17%

Summary

Emergent Biosolutions beats Elicio Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Elicio Therapeutics compare to Bicycle Therapeutics?

Bicycle Therapeutics (NASDAQ:BCYC) and Elicio Therapeutics (NASDAQ:ELTX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

Elicio Therapeutics has lower revenue, but higher earnings than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicycle Therapeutics	$72.86M	4.07	-$218.96M	-$2.73	N/A
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.17	N/A

In the previous week, Bicycle Therapeutics and Bicycle Therapeutics both had 2 articles in the media. Bicycle Therapeutics' average media sentiment score of 0.25 beat Elicio Therapeutics' score of 0.00 indicating that Bicycle Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bicycle Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Elicio Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Elicio Therapeutics has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -311.11%. Bicycle Therapeutics' return on equity of -33.22% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicycle Therapeutics	-311.11%	-33.22%	-27.79%
Elicio Therapeutics	N/A	-1,266.43%	-139.94%

Bicycle Therapeutics currently has a consensus price target of $13.86, suggesting a potential upside of 226.82%. Elicio Therapeutics has a consensus price target of $19.75, suggesting a potential upside of 690.00%. Given Elicio Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Elicio Therapeutics is more favorable than Bicycle Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Elicio Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

86.2% of Bicycle Therapeutics shares are held by institutional investors. Comparatively, 35.0% of Elicio Therapeutics shares are held by institutional investors. 22.0% of Bicycle Therapeutics shares are held by company insiders. Comparatively, 50.9% of Elicio Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Bicycle Therapeutics has a beta of 1.54, suggesting that its stock price is 54% more volatile than the broader market. Comparatively, Elicio Therapeutics has a beta of 1.29, suggesting that its stock price is 29% more volatile than the broader market.

Summary

Bicycle Therapeutics and Elicio Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Elicio Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELTX vs. The Competition

Export

Metric	Elicio Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$67.02M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-1.15	12.66	273.28	25.38
Price / Sales	N/A	1,309.16	613.48	92.60
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	8.33	16.29	12.89	6.14
Net Income	-$39.57M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-11.97%	0.34%	0.61%	-0.27%
1 Month Performance	-20.89%	8.52%	5.73%	0.68%
1 Year Performance	-75.87%	52.66%	25.37%	14.84%

Elicio Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELTX Elicio Therapeutics	1.8939 of 5 stars	$2.50 -2.0%	$19.75 +690.0%	-75.8%	$67.02M	N/A	N/A	N/A
RNAC Cartesian Therapeutics	1.6931 of 5 stars	$9.97 -2.2%	$32.60 +227.0%	-11.0%	$308.30M	$2.80M	N/A	64
FATE Fate Therapeutics	3.2146 of 5 stars	$2.54 -1.2%	$5.90 +132.3%	+142.0%	$307.94M	$6.65M	N/A	550	News Coverage Positive News
YDES YD Bio	N/A	$3.87 -10.8%	N/A	N/A	$307.22M	$596.82K	N/A	N/A	Gap Down
EBS Emergent Biosolutions	3.3717 of 5 stars	$5.96 -0.2%	$10.00 +67.8%	-20.6%	$306.10M	$742.30M	N/A	2,420

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ELTX) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Elicio Therapeutics (ELTX) Competitors

ELTX vs. RNAC, FATE, YDES, EBS, and BCYC

How does Elicio Therapeutics compare to Cartesian Therapeutics?

Summary

How does Elicio Therapeutics compare to Fate Therapeutics?

Summary

How does Elicio Therapeutics compare to YD Bio?

Summary

How does Elicio Therapeutics compare to Emergent Biosolutions?

Summary

How does Elicio Therapeutics compare to Bicycle Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELTX vs. The Competition

Elicio Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Elicio Therapeutics (ELTX) Competitors

ELTX vs. RNAC, FATE, YDES, EBS, and BCYC

How does Elicio Therapeutics compare to Cartesian Therapeutics?

Do analysts prefer ELTX or RNAC?

Do institutionals and insiders believe in ELTX or RNAC?

Which has more volatility & risk, ELTX or RNAC?

Is ELTX or RNAC more profitable?

Does the media refer more to ELTX or RNAC?

Which has higher earnings & valuation, ELTX or RNAC?

Summary

How does Elicio Therapeutics compare to Fate Therapeutics?

Do institutionals & insiders believe in FATE or ELTX?

Which has more volatility and risk, FATE or ELTX?

Does the media favor FATE or ELTX?

Is FATE or ELTX more profitable?

Which has better valuation & earnings, FATE or ELTX?

Do analysts rate FATE or ELTX?

Summary

How does Elicio Therapeutics compare to YD Bio?

Do analysts rate ELTX or YDES?

Does the media refer more to ELTX or YDES?

Is ELTX or YDES more profitable?

Which has higher earnings and valuation, ELTX or YDES?

Do institutionals and insiders believe in ELTX or YDES?

Summary

How does Elicio Therapeutics compare to Emergent Biosolutions?

Which has preferable valuation & earnings, ELTX or EBS?

Which has more volatility & risk, ELTX or EBS?

Do analysts rate ELTX or EBS?

Do insiders and institutionals have more ownership in ELTX or EBS?

Does the media refer more to ELTX or EBS?

Is ELTX or EBS more profitable?

Summary

How does Elicio Therapeutics compare to Bicycle Therapeutics?

Which has stronger earnings and valuation, BCYC or ELTX?

Does the media favor BCYC or ELTX?

Is BCYC or ELTX more profitable?

Do analysts prefer BCYC or ELTX?

Do insiders & institutionals hold more shares of BCYC or ELTX?

Which has more volatility & risk, BCYC or ELTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELTX vs. The Competition

Elicio Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools